Position in EXEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$6,383,317
-$362,162 QoQ
Shares Held
148,830
-3.3% QoQ
Ownership
0.059%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 96.06463750587919.ToString("F0")%
Shared 0.ToString("F0")%
None 3.9353624941208087.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Vident Advisory, LLC holds $44,934,093 across 44 Biotechnology names. EXEL ranks #2 (14.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
16,063 | $7,172,769 | |
| 2 | EXEL |
Exelixis, Inc.
This page
|
148,830 | $6,383,317 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
23,032 | $4,354,199 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,449 | $2,664,834 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
6,457 | $2,136,426 | |
| 6 | INSM |
INSMED Inc
|
9,808 | $1,603,803 | |
| 7 | GMAB |
Genmab A/S
|
48,379 | $1,298,008 | |
| 8 | CYTK |
Cytokinetics Inc
|
17,069 | $1,125,017 |
All Filings in EXEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,383,317 | 148,830 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $6,745,479 | 153,901 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $6,228,699 | 150,816 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $7,466,665 | 169,389 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $10,295,620 | 278,863 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $5,190,603 | 155,874 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $3,088,672 | 119,024 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||